An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Principal Investigator

Macarena De La Fuente

Enrollment Status

Closed

Clinical Trial ID

Institutional Protocol # 20160108

National Clinical Trials Identifier NCT02617589

Clinical Trial Summary

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated
(the MGMT gene is not altered by a chemical change). Patients will receive Nivolumab every
two weeks in addition to radiation therapy, and then every four weeks. They will be compared
to patients receiving standard therapy with temozolomide in addition to radiation therapy.

Phase

Phase 3

Funding Agency/Sponsor

Industrial

Disease

Neurological Cancer

Enrollment Eligibility

Inclusion Criteria:
- Males and Females, age ≥ 18 years old
- Newly-diagnosed brain cancer or tumor called glioblastoma or GBM
- Tumor test result shows MGMT unmethylated type
- Karnofsky performance status of ≥ 70 (able to care for self)
Exclusion Criteria:
- Prior treatment for GBM (other than surgical resection)
- Any known tumor outside of the brain
- Recurrent or secondary GBM
- Active known or suspected autoimmune disease
- Biopsy with less than 20% of tumor removed
Other protocol-defined inclusion/exclusion criteria apply

Contact Information

Phone Number +1 (305) 2434624

Get detailed information on ClinicalTrials.Gov